Type 1 Diabetes BDCP Clinical Study
Evaluate the Safety of Ly3209590 in Patients with type 1 diabetes being treated with multiple daily injection therapy.

Type of Study:
Type 1 diabetes patients who are over 18 years of age

Study Length:
31 Weeks

Target Age/Sex:
over 18 years, Male and Female

Benefits:
Participants will receive at no cost: study product, study materials and study-specific procedures

Staus: Closed

Description:

The BDCP clinical study is for type 1 diabetes patients, 18 years or older, to evaluate the safety of LY3209590 in patients being treated with multiple daily injection therapy.

This Study is Closed.